Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Fuereder

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Investigational New Drugs|August 21, 2023
Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumabMarkus Haas, Alexander Lein, Thorsten Fuereder, et al.
Nutrients|February 25, 2023
The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck CancerMarkus Haas, Alexander Lein, Thorsten Fuereder, et al.
Cancer Treatment Reviews|March 11, 2025
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neckPetr Szturz, Thorsten Fuereder, Ye Guo, et al.
ESMO Open|August 2, 2017
The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Gerald W Prager, et al.
Transplantation|February 24, 2007
Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantationWolfgang Sieghart, Thorsten Fuereder, Katharina Schmid, et al.
Journal of Geriatric Oncology|October 18, 2024
Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric OncologyRupert Bartsch, Daniel Aletaha, Thorsten Fuereder, et al.
Research and Practice in Thrombosis and Haemostasis|July 21, 2025
Longitudinal dynamics of hemostatic biomarkers in patients with cancer receiving immune checkpoint inhibitors vs chemotherapy: results from the Vienna CAT-BLED studyNikola Vladic, Cornelia Englisch, Julia Maria Berger, et al.
Oral Oncology|November 29, 2021
Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II studyThorsten Fuereder, Christoph Minichsdorfer, Martina Mittlboeck, et al.
International Immunopharmacology|August 20, 2023
Low free triiodothyronine and immune-related hyperthyroidism are associated with overall and progression-free survival in head and neck squamous cell carcinoma treated with pembrolizumabMarkus Haas, Alexander Lein, Thorsten Fuereder, et al.
Blood|October 17, 2020
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapyFlorian Moik, Wei-Shin Evelyn Chan, Sarah Wiedemann, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Investigational New Drugs|August 21, 2023
Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumabMarkus Haas, Alexander Lein, Thorsten Fuereder, et al.
Nutrients|February 25, 2023
The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck CancerMarkus Haas, Alexander Lein, Thorsten Fuereder, et al.
Cancer Treatment Reviews|March 11, 2025
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neckPetr Szturz, Thorsten Fuereder, Ye Guo, et al.
ESMO Open|August 2, 2017
The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Gerald W Prager, et al.
Transplantation|February 24, 2007
Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantationWolfgang Sieghart, Thorsten Fuereder, Katharina Schmid, et al.
Journal of Geriatric Oncology|October 18, 2024
Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric OncologyRupert Bartsch, Daniel Aletaha, Thorsten Fuereder, et al.
Research and Practice in Thrombosis and Haemostasis|July 21, 2025
Longitudinal dynamics of hemostatic biomarkers in patients with cancer receiving immune checkpoint inhibitors vs chemotherapy: results from the Vienna CAT-BLED studyNikola Vladic, Cornelia Englisch, Julia Maria Berger, et al.
Oral Oncology|November 29, 2021
Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II studyThorsten Fuereder, Christoph Minichsdorfer, Martina Mittlboeck, et al.
International Immunopharmacology|August 20, 2023
Low free triiodothyronine and immune-related hyperthyroidism are associated with overall and progression-free survival in head and neck squamous cell carcinoma treated with pembrolizumabMarkus Haas, Alexander Lein, Thorsten Fuereder, et al.
Blood|October 17, 2020
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapyFlorian Moik, Wei-Shin Evelyn Chan, Sarah Wiedemann, et al.
Pageof 8